Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Alemtuzumab and multiple sclerosis: therapeutic application.
FDA approval announcement for ofatumumab
Receptos doses first patient in Phase 2 trial for RPC1063 in ulcerative colitis
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
Teva and Active Biotech to continue with the development of NERVENTRA® (laquinimod) for multiple sclerosis following confirmation of CHMP opinion
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate.
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis.
Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis.
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
Interferon beta for secondary progressive multiple sclerosis.
Biogen Idec completes purchase of full rights and control of Tysabri®
Chronic cladribine administration increases amyloid Beta Peptide generation and plaque burden in mice.
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
Glatiramer acetate, an anti-demyelination drug, reduced rats' epileptic seizures induced by pentylenetetrazol via protection of myelin sheath.
The potential teratogenic effects of interferon beta-1a (IFNβ-1a) and interferon beta-1b (IFNβ-1b) on in vitro embryonic development.
A full genome search in multiple sclerosis.
Revimmune (High-Dose Cyclophosphamide) for Autoimmune Diseases
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.
Safety Study of Interferon Beta-1a for Acute Stroke
Prevalence of neurological disorders in Al Quseir, Egypt: methodological aspects.
Development of cladribine at Scripps for hairy cell leukemia and current results.
Pericytes are required for blood-brain barrier integrity during embryogenesis.
A genetic screen identifies genes essential for development of myelinated axons in zebrafish.
Novel MS Drug Offers Good Functional Outcomes
Pages
« first
‹ previous
…
104
105
106
107
108
109
110
111
112
…
next ›
last »